written on 27.06.2014

EU backs Roche's Avastin for hard-to-treat ovarian cancer


The EU Committee for Medicinal Products for Human Use (CHMP) handed down a positive ruling on Roche's blockbuster Avastin, recommending that the European Commission approve the drug for use in women with ovarian cancer that's resistant to platinum-based chemotherapy.